Goldman Further Sweetens Terms on Loan for DuPont Unit’s Sale

Goldman Sachs is reportedly sweetening the terms of the loan package backing the sale of DuPont's biomaterials unit, creating more attractive conditions for potential buyers. This move suggests difficulty in offloading the asset at previous valuations and could signal increasing pressure on private equity or other suitors to finalize a deal, potentially at a revised price point. Investors should watch for the impact on DuPont's stock as the sale progresses and how this reflects broader M&A financing conditions.